Additionally, clinical trial data demonstrate that the efficacy of glioma stem cell-targeted DC vaccines is strongly influenced by molecular biomarkers: the phase II single-center RCT of GSC-DCV revealed superior survival benefits in patients with IDH1 wild-type, TERT mutation, and low B7-H4 expression profiles (54), while the phase II multicenter trial of ICT-107 showed significantly improved median progression-free survival in newly diagnosed GBM patients, particularly those with HLA- A1 methylated tumors (55). This evidence concerns the gene IDH1 and glioblastoma.